CD310 (VEGFR-3) Antibody, anti-human, REAfinity™
Synonyms: FLT-4, FLT41, LMPH1A, PCL, VEGFR3
RECOMBINANT EXTENDED VALIDATION
Bioz Star93/100 Bioz rating
1 Citation
Clone:
REA419 | 9D9
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD310 (VEGFR-3) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
PE
PE-Vio 770
Vio Bright FITC
Vio Bright V423
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-125-977, 130-126-002
Description:
Latex beads were coated with recombinant human CD310 (VEGFR-3) protein and then stained with CD310 (VEGFR-3) antibodies or with the corresponding REA Control (S) antibodies (left peak). Flow cytometry was performed with the MACSQuant® Analyzer.

Application image
Extended validation for CD310 (VEGFR-3) Antibody, anti-human, REAfinity™
Sensitivity
Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD310 (VEGFR-3) (REA419). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD310 (VEGFR-3) Antibody, anti-human, REAfinity™
Overview

Clone REA419 recognizes the human CD310 antigen, a single-pass type I membrane protein also known as vascular endothelial growth factor receptor 3 (VEGFR-3) or Fms-like tyrosine kinase 4 (FLT-4). CD310 is a tyrosine-protein kinase that acts as a cell-surface receptor for the vascular endothelial growth factors VEGF-C and VEGF-D. It plays an essential role in adult lymph-angiogenesis, in the development of the vascular network, and the cardiovascular system during embryonic development. During early embryogenesis all endothelial cells express CD310, while in the adult tissues, CD310 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. CD310 plays a major role in tumor growth and metastatic tumor cell dissemination. The receptor is over-expressed on lymphatic vessels in the vicinity of tumors and on the tumor vasculature and therefore may be an excellent target for an effective cancer intervention.

Additional information: Clone REA419 displays negligible binding to Fc receptors.

Alternative names

FLT-4, FLT41, LMPH1A, PCL, VEGFR3

Detailed product information

Technical specifications

Clone
REA419
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD310 (VEGFR-3)
Molecular mass of antigen [kDa]
150
Distribution of antigen
endothelial cells
Entrez Gene ID
RRID
AB_2928408, AB_2928407, AB_2657324, AB_2657327, AB_2657325, AB_2657328, AB_2889548, AB_2657319, AB_2657318, AB_2904929, AB_2889549, AB_2657326, AB_2657329, AB_2904928

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD310 (VEGFR-3) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?